A Study To Assess The Safety And Efficacy Of a Topical Unani Medicine For Quba (Tinea corporis), Comparing It to Standard Treatments To Explore a Natural, Effective Option For Fungal Skin Infections.

A Randomized , Parallel group , Open label , Active Controlled Clinical Study To Evaluate The Safety and Efficacy of a Topical Unani Formulation In the Management of Quba (Tinea corporis). - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080222

Enrollment

Registered

2025-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Topical Unani Formulation (homogeneous powder as paste in buttermilk): Composition:Babchi seed(psoralea seeds)Ghhongchi(crab s eye)Sarso(black mustard)Kuth (Qust)Tukhm-i-panwad (foetid

Eligibility

Inclusion criteria

Inclusion criteria: 1 Individuals with circumscribed lesions on the body and limbs, presenting with any of the following signs and symptoms: Pruritus and burning sensation Presence of scales Central clearing of the lesion Erythematous papules 2 Additionally, participants must have a positive KOH (10%) smear microscopy from a skin scraping of the active lesion, confirming the presence of dermatophytic hyphae.

Exclusion criteria

Exclusion criteria: 1 Age below 18 years and above 60 years. 2 Patients with other form of tinea infection like,tinea capitis, tinea pedis, tinea manuum, tinea unguium, tinea barbae tinea faciei, etc. 3 Patient with other concomitant diseases like psoriasis & eczema. 4 Patients who have received any topical antifungal therapy within last 2 weeks or oral antifungal therapy in the previous 4 weeks. 5 Patients with known active pulmonary/ cardiovascular/ liver/ renal or neurological diseases. 6 Known cases of Diabetes Mellitus or other immunocompromised disorders (HIV/ AIDS, etc.)/ Malignancies. 7 Patients with long-term history of steroid, cytotoxic and immunosuppressive therapy. 8 History of hypersensitivity to either clotrimazole or unani formulation. 9 Pregnant or lactating women, and women desiring pregnancy. 10 Participants not willing to give consent and to attend treatment schedule regularly.

Design outcomes

Primary

Measure	Time frame
1. Total Signs & Symptoms Score (TSSS) (Clinical Cure) 2. Conversion to Negative Mycology (Mycological Cure) 3. DLQI (Dermatology Life Quality IndexTimepoint: TSSS at Baseline 2nd, 4th and 6th wees. Mycological cure at baseline and on 6th week	—

Secondary

Measure	Time frame
DLQI (Dermatology Life Quality Index) Systemic Safety assessmentTimepoint: At baseline 2nd, 4th & 6th week	—

Countries

India

Contacts

Public ContactDR ANISUR REHMAN SHAIKH

National Research Institute Of Unani Medicine For Skin Disorders

aarzu763@gmail.com9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026